Comera Life Sciences Holdings, Inc.

Equities

CMRA

US20037C1080

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 10:03:31 31/05/2024 pm IST			5-day change	1st Jan Change
0.0227 ^USD	-.--%		-22.53%	-58.73%

30/01	Comera Life Sciences Holdings, Inc. Announces Chief Executive Officer Changes	CI
30/01	Comera Life Sciences Holdings, Inc. Announces Changes to Its Board	CI

Comera Life Sciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 11, 2022 at 03:02 am IST

Comera Life Sciences Holdings, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 0.234922 million compared to USD 0.087767 million a year ago. Net loss was USD 3.08 million compared to USD 0.9137 million a year ago.
For the nine months, sales was USD 0.476982 million compared to USD 0.246498 million a year ago. Net loss was USD 15.04 million compared to USD 3.43 million a year ago.

Latest news about Comera Life Sciences Holdings, Inc.

Comera Life Sciences Holdings, Inc. Announces Chief Executive Officer Changes	31/01	CI
Comera Life Sciences Holdings, Inc. Announces Changes to Its Board	31/01	CI
Comera Life Sciences Holdings, Inc. announced that it has received $1.5 million in funding	29/12	CI
Comera Life Sciences Holdings, Inc.(OTCPK:CMRA) dropped from S&P TMI Index	21/11	CI
Comera Life Sciences Holdings, Inc.(OTCPK:CMRA) dropped from NASDAQ Composite Index	16/11	CI
Comera Life Sciences Holdings, Inc. Appoints Dorothy Clarke to Board of Directors	13/11	CI
Comera Life Sciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Earnings Flash (CMRA) COMERA LIFE SCIENCES Posts Q3 Revenue $136,310	09/11	MT
Comera Life Sciences Holdings, Inc. Announces Resignation of Neal Muni, MD as Executive Vice President and Chief Operating Officer	07/23/07	CI
Comera Life Sciences Holdings, Inc. announced that it has received $4.069993 million in funding	11/23/11	CI
Comera Life Sciences Holdings, Inc. Announces Publication of Study Reinforcing Caffeine's Viscosity Reducing Capabilities	16/23/16	CI
Comera Life Sciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Earnings Flash (CMRA) COMERA LIFE SCIENCES Reports Q2 Revenue $315.1M	10/23/10	MT
Comera Life Sciences Holdings, Inc. Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore(TM) Platform	08/23/08	CI
Comera Life Sciences Holdings, Inc. announced that it expects to receive $4.069993 million in funding	31/23/31	CI
Comera Life Sciences Holdings, Inc. Announces Collaboration with Quality Chemical Laboratories to Secure Proprietary Supply of SQore Excipients	20/23/20	CI
Comera Life Sciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	13/23/13	CI
Earnings Flash (CMRA) COMERA LIFE SCIENCES Reports Q1 Revenue $392.9M	11/23/11	MT
Comera Life Sciences Holdings, Inc. Auditor Raises 'Going Concern' Doubt	17/23/17	CI
Earnings Flash (CMRA) COMERA LIFE SCIENCES Posts Q4 Revenue $156,120	16/23/16	MT
North American Morning Briefing : Payrolls Shocker, China Spat to Weigh on Stocks	06/23/06	DJ
Insider Buy: Comera Life Sciences Holdings	07/23/07	MT
Insider Buy: Comera Life Sciences Holdings	06/23/06	MT
Comera Life Sciences Holdings, Inc. Announces Board Resignations	05/23/05	CI
Comera Life Sciences Holdings, Inc. announced that it has received $3.561238 million in funding	04/23/04	CI

Chart Comera Life Sciences Holdings, Inc.

Duration

Period

Chart Comera Life Sciences Holdings, Inc.

More charts

Company Profile

Comera Life Sciences Holdings, Inc. is a pre-clinical biotechnology company. The Company applies a knowledge of formulation science and technology to transform biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The Company is engaged in developing an internal portfolio of therapeutic product candidates using its proprietary formulation platform, SQore. Its proprietary formulation platform, SQore, is designed to transform biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. Its product programs include CLS-001, a preclinical stage bio better for Crohnâs and Ulcerative Colitis disease, and CLS-002, a preclinical stage bio better for various oncology indications. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to its partnersâ biologic medicines to deliver enhanced SQ formulations.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
COMERA LIFE SCIENCES HOLDINGS, INC.	-58.73%	698K
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B

Other Biotechnology & Medical Research